CALD1 Antibody

What is CALD1 and why is it important in cancer research?

CALD1 encodes caldesmon, a calmodulin- and actin-binding protein that exists in two major isoforms: a high molecular weight form primarily found in smooth muscle cells and a low molecular weight variant present in non-smooth muscle cells. This protein regulates smooth muscle contraction, cell morphology, motility, and cytoplasmic division . Recent studies have established CALD1's critical role in cancer progression through its effects on tumor microenvironment remodeling, particularly in gliomas, bladder cancer, and ovarian cancer . Its importance lies in its potential as both a prognostic biomarker and a therapeutic target, as CALD1 overexpression correlates with poor prognosis in several tumor types .

What are the common applications of CALD1 antibodies in research?

CALD1 antibodies are utilized in multiple research applications including:

• Western blotting for detecting specific CALD1 protein bands (approximately 80 kDa)

• Immunohistochemistry on paraffin-embedded tissue sections of various cancers

• Immunofluorescence studies for cytoskeletal localization

• Analysis of tumor angiogenesis processes

• Investigation of cancer-associated fibroblasts (CAFs) in the tumor microenvironment

• Exploration of immune cell infiltration patterns in cancers

• Studies on cell invasion and metastatic processes in various cancers

How do I select the appropriate CALD1 antibody for my research?

When selecting a CALD1 antibody for your research, consider these methodological factors:

• Target specificity: Verify which region of CALD1 the antibody recognizes (e.g., Lys696-Val793 region for MAB7569)

• Antibody type: Determine whether monoclonal (consistent results, specific epitope) or polyclonal antibodies (broader epitope recognition) are more suitable for your application

• Validated applications: Confirm that the antibody has been validated for your specific application (Western blot, IHC, IF)

• Sample compatibility: Ensure compatibility with your sample type (cell lines, tissue sections, species)

• Isoform recognition: Determine whether you need to detect specific CALD1 isoforms or all variants

Cross-reference antibody specifications with your experimental design and consult published literature using similar methodologies for optimal selection .

How can CALD1 antibodies be used to investigate tumor microenvironment?

CALD1 antibodies provide valuable insights into tumor microenvironment (TME) through several methodological approaches:

• Dual immunofluorescence staining: Co-localize CALD1 with markers of cancer-associated fibroblasts (CAFs) such as ACTA2 to evaluate spatial relationships within the TME

• Multiplex immunohistochemistry: Simultaneously detect CALD1 and immune cell markers to assess correlations between CALD1 expression and immune infiltration

• Correlation analyses with TME components: Use CALD1 antibody staining intensity to quantitatively correlate with:

  • Stromal cell infiltration (particularly CAFs)

  • Macrophage polarization (M0, M2) patterns

  • T cell infiltration (CD8+ T cells)

  • Expression of immune checkpoint molecules

Studies demonstrate that high CALD1 expression correlates positively with immunosuppressive cell populations (M2 macrophages) and negatively with CD8+ T cells, suggesting CALD1's role in establishing an immunosuppressive microenvironment . The ESTIMATE and CIBERSORT algorithms have confirmed significant correlations between CALD1 expression and multiple immune cell populations, making CALD1 antibodies valuable tools for comprehensive TME analysis .

What is the relationship between CALD1 expression and cancer prognosis?

Research utilizing CALD1 antibodies has revealed significant prognostic implications across multiple cancer types:

For methodological approaches to prognostic studies:

• Perform CALD1 immunohistochemistry on patient cohorts with long-term follow-up

• Establish optimal cut-off values for "high" versus "low" CALD1 expression

• Conduct Kaplan-Meier survival analyses with log-rank tests

• Validate findings using multivariate Cox regression analyses to control for confounding factors

• Correlate CALD1 expression with established clinical parameters (stage, grade, molecular subtypes)

How does CALD1 contribute to cancer metastasis and invasion?

CALD1 influences cancer metastasis and invasion through cytoskeletal regulation and focal adhesion dynamics:

• F-actin interaction: CALD1 binds to F-actin, regulating stress fiber formation and stability

• Focal adhesion modulation: In ovarian cancer, reduced CALD1 expression decreases cytoskeleton-Vinculin interactions, resulting in diminished focal adhesions and enhanced invasiveness

• EMT pathway activation: GSEA analysis indicates that CALD1 positively correlates with epithelial-to-mesenchymal transition pathways

• ECM remodeling: CALD1 is involved in multiple microenvironment remodeling pathways including ECM receptor interaction and focal adhesion

To investigate these mechanisms:

• Perform CALD1 knockdown/overexpression experiments in cancer cell lines

• Analyze cytoskeletal changes through F-actin staining

• Quantify focal adhesions using Vinculin immunofluorescence

• Measure invasion capacity through Transwell or 3D matrix invasion assays

• Evaluate EMT marker expression changes following CALD1 modulation

These methodological approaches have demonstrated that CALD1's role in invasion may be cancer-type specific, with reduced expression promoting invasion in ovarian cancer but elevated expression correlating with progression in glioma and bladder cancer .

What are the optimal protocols for CALD1 immunohistochemistry in different cancer tissues?

Successful CALD1 immunohistochemistry requires optimized protocols based on tissue type:

• Tissue preparation:

  • Fix tissues in 10% neutral buffered formalin for 24-48 hours

  • Process and embed in paraffin

  • Section at 4-5 μm thickness

• Antigen retrieval methods:

  • Heat-induced epitope retrieval in citrate buffer (pH 6.0) is generally effective

  • For brain tissues, EDTA buffer (pH 9.0) may provide superior results

• Antibody optimization:

  • For paraffin-embedded sections, dilution ranges of 1:250 (as used for CALD1 in bladder cancer studies)

  • Incubation times typically 30-60 minutes at room temperature or overnight at 4°C

• Detection systems:

  • Biotin-streptavidin HRP systems work well for CALD1 detection

  • For multiplex staining, consider fluorescent secondary antibodies

• Controls and validation:

  • Include positive controls (smooth muscle cells often serve as internal positive controls)

  • Use isotype-matched IgG as negative controls

  • Consider dual staining with other markers (ACTA2 for CAFs, CD206 for M2 macrophages) to validate specificity

For automated systems, the BenchMark GX automatic immunohistochemical staining system has been successfully employed with CALD1 antibodies at 1:250 dilution with 32-minute incubation periods .

What are effective strategies for quantifying CALD1 expression in research samples?

Quantification of CALD1 expression requires standardized approaches:

• Immunohistochemistry quantification:

  • H-score method: Calculate H-score = Σ(I × P), where I is staining intensity (0-3) and P is percentage of cells (0-100%)

  • Digital image analysis using software (ImageJ, QuPath) for automated quantification

  • Tissue microarray (TMA) approaches for high-throughput analysis

• Western blot quantification:

  • Normalization to housekeeping proteins (β-actin, GAPDH)

  • Densitometric analysis using software like ImageJ

  • For the ~80 kDa CALD1 band, reducing conditions and Immunoblot Buffer Group 1 are recommended

• Gene expression quantification:

  • qRT-PCR with appropriate reference genes

  • RNA-seq with normalization methods (FPKM, TPM)

  • log2 transformation of expression values for statistical analysis

• Statistical analysis approaches:

  • Compare high vs. low expression groups using the Wilcoxon test

  • For more than two groups, employ the Kruskal test

  • For correlation with other markers, use Pearson (normally distributed data) or Spearman (non-normal distribution) tests

These quantification approaches have enabled researchers to establish significant correlations between CALD1 expression levels and cancer progression, immune infiltration patterns, and patient outcomes .

How should I design CALD1 knockdown/overexpression experiments to study its function?

When designing experiments to modulate CALD1 expression:

• Knockdown strategies:

  • siRNA: For transient knockdown with multiple siRNA sequences targeting different regions of CALD1

  • shRNA: For stable knockdown with puromycin selection

  • CRISPR/Cas9: For complete knockout using lentiviral-based vectors as employed in U251 and LN229 glioblastoma cell lines

• Overexpression approaches:

  • Plasmid-based overexpression with full-length CALD1 cDNA

  • Consider both high and low molecular weight isoforms for comprehensive studies

  • Use appropriate selection markers (puromycin at 1 μg/mL has been effective)

• Validation of modulation:

  • Western blot: Confirm protein level changes

  • qRT-PCR: Verify transcript level alterations

  • Immunofluorescence: Assess changes in subcellular localization and expression patterns

• Functional assays to evaluate effects:

  • Migration assays (wound healing, transwell)

  • Invasion assays (Matrigel-coated transwell)

  • Cytoskeletal staining to assess F-actin organization

  • Adhesion assays with various substrates (collagen, fibronectin)

  • Co-culture experiments with immune cells to assess immune modulation

• Controls:

  • Non-targeting siRNA/shRNA controls

  • Empty vector controls for overexpression

  • Multiple cell lines to ensure reproducibility (e.g., both U251 and LN229 for glioma studies)

These experimental approaches have successfully demonstrated CALD1's role in cytoskeletal organization, cancer cell invasion, and immune cell interactions in various cancer models .

How do I troubleshoot non-specific binding when using CALD1 antibodies?

When encountering non-specific binding with CALD1 antibodies:

• Optimization of blocking conditions:

  • Extend blocking time (1-2 hours at room temperature)

  • Try different blocking agents (5% BSA, 5% normal serum, commercial blocking buffers)

  • Add 0.1-0.3% Triton X-100 for better penetration in IF applications

• Antibody dilution adjustments:

  • Test a range of dilutions (typically 1:100 to 1:1000)

  • For Western blot applications, 2 μg/mL has been effective for CALD1 detection

  • For immunofluorescence, 10 μg/mL has been successfully used

• Washing optimization:

  • Increase number of washes (5-6 times)

  • Extend washing duration (10 minutes per wash)

  • Use PBS-T (PBS with 0.05-0.1% Tween-20) for more stringent washing

• Antibody specificity verification:

  • Perform peptide competition assays

  • Include CALD1-negative cell lines as controls

  • Compare results with alternative CALD1 antibodies

• Secondary antibody considerations:

  • Use highly cross-adsorbed secondary antibodies

  • Consider secondary antibody-only controls

  • For fluorescent applications, NorthernLights™ 557-conjugated Anti-Mouse IgG has shown good specificity

These troubleshooting approaches help ensure specific detection of the ~80 kDa CALD1 band in Western blots and precise cytoskeletal localization in immunofluorescence applications .

How can I validate the specificity of my CALD1 antibody results?

Rigorous validation of CALD1 antibody specificity requires multiple complementary approaches:

• Multi-method concordance:

  • Compare protein detection across different techniques (WB, IHC, IF)

  • Verify that subcellular localization is consistent with known cytoskeletal association

  • Confirm expected molecular weight (~80 kDa) in Western blots

• Genetic manipulation validation:

  • Use CALD1 knockdown/knockout samples as negative controls

  • Perform CALD1 overexpression to confirm increased signal

  • Employ rescue experiments to demonstrate specificity

• Cross-reactivity assessment:

  • Test antibody in multiple cell types with known CALD1 expression levels

  • WI-38 human lung fibroblast cells provide a reliable positive control

  • Include tissue sections with known CALD1 expression patterns

• Orthogonal technique validation:

  • Correlate protein detection with mRNA expression (qRT-PCR, RNA-seq)

  • Compare with mass spectrometry-based protein identification

  • Use alternative antibodies targeting different CALD1 epitopes

• Biological correlates verification:

  • Confirm expected associations with biological processes (e.g., correlation with stromal scores, immune infiltration patterns)

  • Verify anticipated prognostic relationships in patient cohorts

These validation approaches are critical for ensuring reliable CALD1 detection, particularly in complex tumor microenvironments where multiple cell types may express this protein at varying levels .

What are the best practices for analyzing contradictory data regarding CALD1 function in different cancer types?

When facing contradictory findings regarding CALD1 function across cancer types:

• Context-dependent analysis framework:

  • Compare experimental conditions systematically (cell types, assays, endpoints)

  • Note cancer-specific differences in molecular subtypes and microenvironments

  • Consider that CALD1 promotes progression in glioma and bladder cancer but reduced CALD1 enhances invasion in ovarian cancer

• Isoform-specific investigations:

  • Determine which CALD1 isoforms are being studied (high vs. low molecular weight)

  • Use isoform-specific antibodies or primers when possible

  • Different isoforms may have distinct functions in various cancer contexts

• Methodological reconciliation:

  • Create a standardized analysis pipeline across studies

  • Re-analyze raw data using consistent statistical approaches

  • Use meta-analysis techniques to integrate findings across studies

• Pathway analysis integration:

  • Map contradictory findings to specific signaling pathways

  • Use GSEA analysis to identify consistently enriched pathways despite seemingly contradictory results

  • Consider that CALD1 consistently affects ECM remodeling and focal adhesion pathways

• Multi-omics approach:

  • Integrate protein, mRNA, and epigenetic data

  • Consider post-translational modifications that might explain functional differences

  • Employ single-cell analysis to resolve cell type-specific effects

This systematic approach has helped reconcile seemingly contradictory findings, revealing that while CALD1 generally correlates with stromal components and immunosuppressive microenvironments across cancers, its specific effects on invasion and metastasis may be context-dependent .

How might CALD1 antibodies be utilized for developing new cancer therapeutic strategies?

CALD1 antibodies could contribute to therapeutic development through several innovative approaches:

• Biomarker development:

  • Patient stratification for clinical trials based on CALD1 expression patterns

  • Monitoring treatment response in tumors where CALD1 correlates with progression

  • Identifying patients likely to benefit from immunotherapy based on CALD1-associated immune profiles

• Target validation strategies:

  • In vivo imaging using labeled CALD1 antibodies to visualize tumor-stromal interactions

  • Therapeutic antibody development targeting CALD1-mediated pathways

  • Combination therapy approaches targeting both CALD1 and immune checkpoint molecules

• Novel intervention approaches:

  • Development of inhibitors disrupting CALD1's interaction with cytoskeletal components

  • Targeting CALD1-mediated immunosuppressive mechanisms in the tumor microenvironment

  • Engineering CAR-T cells to recognize CALD1-expressing stromal components

• Immunotherapy enhancement:

  • Modulating CALD1 expression to reduce immunosuppressive M2 macrophage polarization

  • Enhancing CD8+ T cell infiltration by targeting CALD1-dependent pathways

  • Combining CALD1 inhibition with immune checkpoint blockade

These approaches leverage the finding that CALD1 contributes to immunosuppressive microenvironments in multiple cancers, suggesting that inhibition of CALD1's activity could enhance immune responses against tumors .

What emerging technologies could enhance CALD1 antibody research?

Cutting-edge technologies that could advance CALD1 antibody research include:

• Single-cell analysis methods:

  • Single-cell RNA sequencing to resolve cell type-specific CALD1 expression patterns

  • Mass cytometry (CyTOF) for high-dimensional protein profiling of CALD1 and associated markers

  • Single-cell spatial transcriptomics to map CALD1 expression within the tumor microarchitecture

• Advanced microscopy techniques:

  • Super-resolution microscopy for detailed analysis of CALD1-cytoskeletal interactions

  • Live-cell imaging with fluorescently tagged CALD1 to track dynamic processes

  • Intravital microscopy to observe CALD1-expressing cells in living tumors

• CRISPR screening approaches:

  • Genome-wide CRISPR screens to identify synthetic lethal interactions with CALD1

  • CRISPRa/CRISPRi for reversible modulation of CALD1 expression

  • Base editing technologies for precise modification of CALD1 sequences

• Proteomics innovations:

  • Proximity labeling techniques to identify CALD1 interaction partners

  • Phosphoproteomics to map CALD1 phosphorylation dynamics

  • Targeted protein degradation approaches for rapid CALD1 depletion

• Artificial intelligence integration:

  • Machine learning for automated analysis of CALD1 staining patterns

  • AI-driven prediction of CALD1-dependent patient outcomes

  • Deep learning for identification of novel CALD1-related therapeutic targets

These technological advancements will enable more precise characterization of CALD1's roles in cancer progression and potentially identify new therapeutic vulnerabilities based on CALD1 expression patterns .